Oxaliplatin for chemotherapeutic treatment and prevention of experimental peritoneal carcinomatosis in rats comparing the intraperitoneal and intravenous application mode

European Surgical Research

Volumn 44, Issue 2, 2010, Pages 74-81

  Hribaschek, A ^a   Meyer, F ^a   Ridwelski, K ^a   Kuester, D ^a   Lippert, H ^a  

^a UNIVERSITY HOSPITAL MAGDEBURG   (Germany)

Author keywords

Animal experiment; Antineoplastic treatment; Chemotherapy; Experimental peritoneal carcinomatosis; Intraperitoneal drug application; Intravenous administration route; Oxaliplatin

Indexed keywords

ELOXANTIN; OXALIPLATIN; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CANCER CELL; CANCER CHEMOTHERAPY; CARCINOMATOUS PERITONITIS; CATHETER INFECTION; CAUSE OF DEATH; CELL TRANSFER; COLORECTAL CANCER; CONTROLLED STUDY; DRUG DOSE REDUCTION; INTESTINE NECROSIS; LAPAROTOMY; NONHUMAN; PERITONEUM; PERITONEUM CANCER; PERITONEUM TUMOR; PRIORITY JOURNAL; RAT; TREATMENT OUTCOME; TUMOR GROWTH;

ADENOCARCINOMA; ANIMALS; ANTINEOPLASTIC AGENTS; CARCINOMA; CELL DIVISION; CELL LINE, TUMOR; COMBINED MODALITY THERAPY; DISEASE MODELS, ANIMAL; INJECTIONS, INTRAVENOUS; ORGAN SIZE; ORGANOPLATINUM COMPOUNDS; PERITONEAL NEOPLASMS; RATS;

EID: 73249122467     PISSN: 0014312X     EISSN: None     Source Type: Journal    
DOI: 10.1159/000269932     Document Type: Article

References (45)

1. Chu DZ, Lang NP, Thompson C, Osteen PK, Westbrook KC: Peritoneal carcinomatosis in nongynecologic malignancy. A prospective study of prognostic factors. Cancer 1989; 63: 364-367.
2. de Bree E, Wittkamp AJ, Zoetmulder FA: Intraperitoneal chemotherapy for colorectal cancer. J Surg Oncol 2002; 79: 46-61.
3. Sadeghi B, Arvieux C, Glehen O, Beaujard AC, Rivoire M, Baulieux J, Fontaumard E, Brachet A, Caillot JL, Faure JL, Porcheron J, Peix JL, Francois Y, Vignal J, Gilly FN: Peritoneal carcinomatosis from non-gynecologic malignancies: results of the EVOCAPE 1 muticentric prospective study. Cancer 2000; 88: 358-363.
4. Sugarbaker PH, Yonemura Y: Palliation with a glimmer of hope: management of resectable gastric cancer with peritoneal carcinomatosis. Hepatogastroenterology 2001; 48: 1238-1247.
5. Yonemura Y, Nojima N, Kaji M, Fujimura T, Itoh H, Ninomiya I, Miyazaki I, Endo Y, Sasaki T: E-cadherin and urokinase-type plasminogen actvator tissue status in gastric carcinoma. Cancer 1999; 76: 941-953.
6. Leather AJ, Kocjan G, Savage F, Hu W, Yiu CY, Boulos PB, Northover JM, Phillips RK: Detection of free malignant cells in the peritoneal cavity before and after resection of colorectal cancer. Dis Colon Rectum 1994; 37: 814-819.
7. Skipper D, Cooper AJ, Marston JE, Taylor I: Exfoliated cells and in vitro growth in colorectal cancer. Br J Surg 1987; 74: 1049-1052.
8. Kotanagi H, Saito Y, Yoshioka T, Koyama K: Characteristics of two cancer cell lines derived from metastatic foci in liver and peritoneum of a patient with colon cancer. J Gastroenterol 1998; 33: 842-849.
9. Schlaeppi M, Ruegg C, Tran-Thang C, Chapuis G, Tevaearai H, Lahm H, Sordat B: Role of integrins and evidence for two distinct mechanism mediating human colorectal carcinoma cell interaction with peritoneal mesothelial cells and extracellular matrix. Cell Adhes Commun 1997; 4: 439-455.
10. Yonemura Y, Endo Y, Yamaguchi T, et al: Roles of VLA-2 and VLA-3 on the formation of peritoneal dissemination in gastric cancer. Int J Oncol 1996; 8: 925-931. (Pubitemid 26144913)
11. Yung S, Coles GA, Davies M: IL-1 beta, a major stimulator of hyaluronan synthesis in vitro of human peritoneal mesothelial cells: relevance to peritonitis in CAPD. Kidney Int 1996; 50: 1337-1343.
12. Akedo H, Shinkai K, Mukai M, Mori Y, Tateishi R, Tanaka K, Yamamoto R, Morishita T: Interaction of rat ascites hepatoma cells with cultured mesothelial cell layers: a model for tumor invasion. Cancer Res 1986; 46: 2416-2422.
13. Bruckner HW, Stablein DM: Sites of treatment failure: gastrointestinal tumor study group analysis of gastric, pancreatic and colorectal trials. Cancer Treat Symp 1983; 2: 199-210.
14. Yonemura Y, Endo Y, Fujita H, Kimura K, Sugiyama K, Momiyama N, Shimada H, Sasaki T: Inhibition of peritoneal dissemination in human gastric cancer by MMP-7-specific antisense oligonucleotide. J Exp Clin Cancer Res 2001; 20: 205-212.
15. Aparicio T, Kermorgant S, Dessirier V, Lewin MJ, Lehy T: Matrix metalloproteinase inhibition prevents colon cancer peritoneal carcinomatosis development and prolongs survival in rats. Carcinogenesis 1999; 20: 1445-1451.
16. Pross M, Lippert H, Mantke R, Kruger S, Gunther T, Marusch F, Halangk W, Schulz HU: A proteinase inhibitor decreases tumor growth in a laparoscopic rat model. Surg Endosc 2001; 15: 882-885.
17. Forth W, Henschler D, Rummel W, Starke K (eds): Pharmakologie und Toxikologie. Leipzig, Wissenschaftsverlag, 1992, ed 6, p 66.
18. de Gramont A, Figer A, Seymour M, Homerin M, Hmissi A, Cassidy J, Boni C, Cortes- Funes H, Cervantes A, Freyer G, Papamichael D, Le Bail N, Louvet C, Hendler D, de Braud F, Wilson C, Morvan F, Bonetti A: Leucovorin and 5-FU with or without oxaliplatin as first-line treatment in advanced colorectal cancer. J Clin Oncol 2000; 18: 2938-2947.
19. Giacchetti S, Perpoint B, Zidani R, Le Bail N, Faggiuolo R, Focan C, Chollet P, Llory JF, Letourneau Y, Coudert B, Bertheaut-Cvitkovic F, Larregain-Fournier D, Le Rol A, Walter S, Adam R, Misset JL, Levi F: Phase III multicenter randomized trial of oxaliplatin added to chronomodulated 5-FU-leucovorin as first-line treatment of metastatic colorectal cancer. J Clin Oncol 2000; 18: 136-147.
20. Cass AW, Million RR, Pfaff WW: Patterns of recurrence following surgery alone for adenocarcinoma of the colon and rectum. Cancer 1976; 37: 2861-2865.
21. Malcolm AW, Perencevich NP, Olson RM, Hanley JA, Chaffey JT, Wilson RE: Analysis of recurrence patterns following curative resection for carcinoma of the colon and rectum. Surg Gynecol Obstet 1981; 152: 131-136.
22. Michelassi F, Vannucci L, Ayala JJ, Chappel R, Goldberg R, Block GE: Local recurrence after curative resection of colorectal cancer. Surgery 1990; 108: 787-793.
23. Willett CG, Tepper JE, Cohen AM, Orlow E, Welch CE: Failure patterns following curative resection of colonic carcinoma. Ann Surg 1984; 200: 685-690.
24. Scheithauer W, Kornek GV, Marczell A, Karner J, Salem G, Greiner R, Burger D, Stoger F, Ritschel J, Kovats E, Vischer HM, Schneeweiss B, Depisch D: Combined intravenous and intraperitoneal chemotherapy with 5-FU + leucovorin vs 5-FU + levamisole for adjuvant therapy of resected colon carcinoma. Br J Cancer 1998; 77: 1349-1354.
25. Nordlinger B, Rougier P, Arnaud JP, Debois M, Wils J, Ollier JC, Grobost O, Lasser P, Wals J, Lacourt J, Seitz JF, Guimares dos Santos J, Bleiberg H, Mackiewickz R, Conroy T, Bouché O, Morin T, Baila L, van Cutsem E, Bedenne L: Adjuvant regional chemotherapy and systemic chemotherapy versus systemic chemotherapy alone in patients with stage II-III colorectal cancer: a multicentre randomised controlled phase III trial. Lancet Oncol 2005; 6: 459-468.
26. Maruyama M, Takamatsu S, Sugano N, Ebuchi M, Endo M, Yuasa Y: Experimental study on intraperitoneal sequential MTX/5-FU therapy for peritoneal seeding in comparison with intravenous administration. Gan To Kagaku Ryoho 1997; 24: 2131-2136.
27. Shiu M, Fortner J: Intraperitoneal hyperthermic treatment of implanted peritoneal cancer in rats. Cancer Res 1980; 40: 4081-4084.
28. Benoit L, Duvillard C, Beltramo JL, Brunet- Lecomte P, Chauffert B: Intraperitoneal cisplatin plus epinephrine and surgical debulking for the treatment of advanced peritoneal carcinomatosis in the rat. Gastroenterol Clin Biol 2000; 24: 26-30.
29. Jeung HC, Rha SY, Jang WI, Noh SH, Chung HC: Treatment of advanced gastric cancer by palliative gastrectomy, cytoreductive therapy and postoperative intraperitoneal chemotherapy. Br J Surg 2002; 89: 460-466.
30. Fujimoto S, Takahashi M, Mutou T, Kobayashi K, Toyosawa T: Successful intraperitoneal hyperthermic chemoperfusion for the prevention of postoperative peritoneal recurrence in patients with advanced gastric carcinoma. Cancer 1999; 85: 529-534.
31. Horsell KW, Merten S, Clingan P, King DW, Morris DL: Peritonectomy and intraperitoneal chemotherapy in appendical and colorectal cancer. Aust N Z J Surg 1999; 69: 729-732.
32. Sugarbaker PH, Jablonski KA: Prognostic features of 51 colorectal and 130 appendical cancer patients with peritoneal carcinomatosis treated by cytoreductive surgery and intraperitoneal chemotherapy. Ann Surg 1995; 221: 124-132.
33. Sautner T, Hofbauer F, Depisch D, Schiessel R, Jakesz R: Adjuvant intraperitoneal cisplatin chemotherapy does not improve longterm survival after surgery for advanced gastric cancer. J Clin Oncol 1994; 12: 970-974.
34. Samel S, Singal A, Becker H, Post S: Problems with intraperitoneal chemotherapy for advanced gastric cancer. Eur J Surg Oncol 2000; 26: 222-226.
35. Rosen HR, Jatzko G, Repse S, Potrc S, Neudorfer H, Sandbichler P, Zacherl J, Rabl H, Holzberger P, Lisborg P, Czeijka M: Adjuvant intraperitoneal chemotherapy with carbonabsorbed mitomycin in patients with gastric cancer: results of a randomized multicenter trial of the Austrian working group for surgical oncology. J Clin Oncol 1998; 16: 2733-2738.
36. Fass J, Jansen M, Zengel K, Reinecke T, Asshoff G, Schumpelick V: Results of intraperitoneal active charcoal-mitomycin C therapy of stomach carcinoma with serosa invasion. Langenbecks Arch Chir Suppl 1998; 115: 1363-1366.
37. Verwaal VJ, Zoetmulder FAN: Follow-up patients treated by cytoreduction and chemotherapy for peritoneal carcinomatosis of colorectal origin. Eur J Surg Oncol 2004; 30: 280-285.
38. Elias D, Bonnay M, Puizillou JM, Antoun S, Demirdjian S, El OA, Pignon JP, Drouard- Troalen L, Ouellet JF, Ducreux M: Heated intra-operative intraperitoneal oxaliplatin after complete resection of peritoneal carcinomatosis: pharmacokinetics and tissue distribution. Ann Oncol 2002; 13: 267-272. (Pubitemid 34704979)
39. Elias DM, Sideris L: Pharmacokinetics of heated intraoperative intraperitoneal oxaliplatin after complete resection of peritoneal carcinomatosis. Surg Oncol Clin N Am 2003; 12: 755-769, xiv.
40. Elias D, Pocard M, Sideris L, Edè C, Ducreux M, Boige V, Lasser P: Preliminary results of intraperitoneal chemohyperthermia with oxaliplatin in peritoneal carcinomatosis of colorectal origin. Br J Surg 2004; 91: 455-456. (Pubitemid 38491115)
41. Elias D, Sideris L, Pocard M, Edè C, Ben Hassouna D, Ducreux M, Boige V, Côté JF, Lasser P: Efficacy of intraperitoneal chemohyperthermia with oxaliplatin in colorectal peritoneal carcinomatosis. Preliminary results in 24 patients. Ann Oncol 2004; 15: 781-785. (Pubitemid 38714740)
42. Atallah D, Marsaud V, Radanyi C, Kornprobst M, Rouzier R, Elias D, Renoir JM: Thermal enhancement of oxaliplatin-induced inhibition of cell proliferation and cell cycle progression in human carcinoma cell lines. Int J Hyperthermia 2004; 20: 405-419.
43. Elias D, Raynard B, Bonnay M, Pocard M: Heated intra-operative intraperitoneal oxaliplatin alone and in combination with intraperitoneal irinotecan: pharmacologic studies. Eur J Surg Oncol 2006; 32: 607-613.
44. Elias D, Benizri E, Di Pietrantonio D, Menegon P, Malka D, Raynard B: Comparison of two kinds of intraperitoneal chemotherapy following complete cytoreductive surgery of colorectal peritoneal carcinomatosis. Ann Surg Oncol 2007; 14: 509-514.
45. Elias D, Pocard M, Goere D: HIPEC with oxaliplatin in the treatment of peritoneal carcinomatosis of colorectal origin. Cancer Treat Res 2007; 134: 303-318.